 | Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
The rising prevalence of obesity is a growing problem in developed countries, with 32% of Americans and 17% of EU residents considered obese in 2008. The condition is associated with a range of severe co-morbidities, the most significant of which include asthma, cardiovascular disease, cancer, diabetes, hypertension and kidney disease. Obesity-related treatments cost healthcare payors billions of dollars each year, and the market for medications is steadily expanding as incidence of obesity continues to increase. Stringent regulations have restricted the amount of medications currently available, however many currently marketed products are failing to meet consumer needs. Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment is a new report published by Business Insights that explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area. The potential of leading obesity drug candidates is assessed and over 100 compounds are identified across pre-clinical, Phase I, Phase II and Phase III development. Forecasts of future sales are also provided, based upon trends in obesity drug usage, projected prevalence rates and the approval potential of emerging products. Explore the latest trends and innovations in obesity treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report.Some key findings from this report• An estimated 17% (85m people) of the EU population are obese and a further 32% (160m people) are overweight. The average rate of obesity in the US is forecast to reach 40% by 2010. • US sales of obesity drugs more than tripled in 2007 to reach $421m following the introduction of Alli, which accounted for 71% of total revenue. Strong support from GlaxoSmithKline will stimulate further expansion for Alli in both the US and EU. • The majority of weight loss products currently marketed have proven to be ineffective, with only a small proportion of consumers having been able to achieve and maintain weight loss. • The US and European obesity drug markets will expand at a combined CAGR of 23.3% between 2008-2012. This growth will be driven by the launch of several products currently in late stage development, and increase revenues to an estimated $3.1b by 2012. • A large number of novel obesity medications are currently under development, many of which represent novel approaches to the treatment of obesity and new drug classes such as CB1 antagonists and serotonin receptor agonists. Obesity Drug Markets in the US and EUThe rising prevalence of obesity is a growing problem in developed countries, with 32% of Americans and 17% of EU residents considered obese in 2008. The condition is associated with a range of severe co-morbidities, the most significant of which include asthma, cardiovascular disease, cancer, diabetes, hypertension and kidney disease. Obesity-related treatments cost healthcare payors billions of dollars each year, and the market for medications is steadily expanding as incidence of obesity continues to increase. Stringent regulations have restricted the amount of medications currently available, however many currently marketed products are failing to meet consumer needs. ‘Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment’ is a new report published by Business Insights that explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area. The potential of leading obesity drug candidates is assessed and over 100 compounds are identified across pre-clinical, Phase I, Phase II and Phase III development. Forecasts of future sales are also provided, based upon trends in obesity drug usage, projected prevalence rates and the approval potential of emerging products.Explore the latest trends and innovations in obesity treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report... Top five reasons to order your copy today• Examine the major issues surrounding obesity in the US and EU with this report’s detailed analysis of co-morbidities, prevalence rates by sub-population, socioeconomic impacts, regulatory trends and the latest medical intelligence from this rapidly evolving treatment area. • Evaluate the relative safety, efficacy and cost of currently marketed obesity drugs with this report’s comparative analysis of Rx and OTC medications including Alli, Meridia, Xenical and Accomplia. • Explore emerging obesity treatments with details and descriptions of 146 drugs at various stages of pipeline development and assess the safety, efficacy and cross-indication potential of leading obesity drug candidates such as Lorcaserin hydrochloride, Lepislim, Taranabant, Contrave, CP-945,598 and Qnexa. • Forecast sales for obesity medications in the US and EU through to 2013, measure the performances of currently marketed drugs in each region and discover how competitive dynamics will change in the future. • Identify the strategies that offer the greatest success potential within the expanding market for obesity treatments and understand the challenges currently facing companies within this therapeutic area. Key issues examined in this report...• Full pipelines reflect demand. Increasing proportions of both US andEU populations are becoming overweight, obese, morbidly obese orsuper obese, creating a growing need for treatments in this field. Alarge number of pharma companies are currently developing suchtreatments, most of which are in the early stages of development.• Consumer dissatisfaction. Consumers are largely dissatisfied withcurrent obesity products, as most require significant lifestyle changes(ie. diet and exercise) that can often prove difficult to accomodate.• Rising regulatory scrutiny. Heightened scrutiny, particularly at theFDA, is causing approval delays and denials for all drug candidates.Sanofi-Aventis’s new obesity drug, Acomplia, is widely availableoutside the US but was rejected by the FDA on safety concerns.• Non-prescription availability. Alli’s switch from Rx to OTC usage in2007 reinvigorated the US market for obesity treatments.GlaxoSmithKline is currently pursuing a similar switch in Europe withapproval expected during 2009 at the latest. Your questions answered• How can the rising trend of obesity in the US and EU be countered effectively?• Which approaches to obesity management will experience the most growth through to 2012?• Why was Alli able to achieve significantly more OTC sales than Xenical?• Why are there relatively few advanced-stage drug candidates for obesity?• How will the competitive dynamics of leading obesity medications change in the US and EU over the 2008-2012 period?• Why is the approval late-stage obesity drugs under threat?• Which newly identified condition is obesity related to?Publication date: Jul-08 Format: PDF Pages: 148
Table of Contents
Price: $3,835.00 / €2,563.31
|
|
